AR069260A1 - Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. - Google Patents
Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento.Info
- Publication number
- AR069260A1 AR069260A1 ARP080104919A ARP080104919A AR069260A1 AR 069260 A1 AR069260 A1 AR 069260A1 AR P080104919 A ARP080104919 A AR P080104919A AR P080104919 A ARP080104919 A AR P080104919A AR 069260 A1 AR069260 A1 AR 069260A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorder
- depression
- disease
- piperazine
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- -1 2, 4-DIMETHYLPHENYL Chemical class 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 8
- 208000002193 Pain Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 3
- 230000003542 behavioural effect Effects 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 2
- 201000006062 Asperger syndrome Diseases 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 2
- 230000016571 aggressive behavior Effects 0.000 abstract 2
- 238000013019 agitation Methods 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000012672 seasonal affective disease Diseases 0.000 abstract 2
- 230000035882 stress Effects 0.000 abstract 2
- 201000009032 substance abuse Diseases 0.000 abstract 2
- 206010000117 Abnormal behaviour Diseases 0.000 abstract 1
- 201000009487 Amblyopia Diseases 0.000 abstract 1
- 206010002652 Anorgasmia Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000001836 Firesetting Behavior Diseases 0.000 abstract 1
- 206010020400 Hostility Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010022998 Irritability Diseases 0.000 abstract 1
- 206010024870 Loss of libido Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010034158 Pathological gambling Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000011962 Substance-induced mood disease Diseases 0.000 abstract 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000037328 acute stress Effects 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 208000025748 atypical depressive disease Diseases 0.000 abstract 1
- 208000014679 binge eating disease Diseases 0.000 abstract 1
- 208000026725 cyclothymic disease Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000001544 dysphoric effect Effects 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000015046 intermittent explosive disease Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 206010023461 kleptomania Diseases 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 201000004645 pyromania Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 208000002271 trichotillomania Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002618 waking effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Un método para tratar una enfermedad del grupo: trastorno del ritmo circadiano; dificultades para conciliar el sueno; despertares nocturnos; despertares de madrugada; respiracion dificultosa durante el sueno; síndrome de hipopnea; depresion severa; trastorno distímico; ciclotimia; depresion postrante; depresion atípica; trastorno del humor asociado con un trastorno médico generalizado; trastorno del humor inducido por sustancias; depresion recurrente; depresion de episodio unico; depresion pediátrica; depresion postapoplejía; trastorno disforico peri-, pre- o post-menopáusico; trastorno afectivo estacional (TAE); agresion y agitacion en la demencia o enfermedad de Alzheimer; trastornos compulsivos y del espectro atencional en el TDAH, autismo o síndrome de Asperger; leucariosis; enfermedad de los vasos capilares; depresion asociada con abuso, irritabilidad, hostilidad, trastornos del sueno, fatiga, enfermedad de Huntington, esclerosis multiple, ansiedad (depresion ansiosa), dolor, dolor del tracto gastrointestinal o síndrome de colon irritable (SCI); trastorno de ansiedad general asociada con dolor; trastorno del control de los impulsos; trastorno explosivo intermitente; cleptomanía; piromanía; adiccion al juego; tricotilomanía; síntomas negativos de la esquizofrenia; deterioro cognitivo leve; demencia vascular; deterioro cognitivo asociado al síndrome de Down, mutaciones del gen tph, TDAH, epilepsia, lesion traumática cerebral o síndrome de Asperger; agresion y agitacion en la demencia y enfermedad de Alzheimer; síndrome de fatiga cronica; trastorno relacionado con el estrés; estrés agudo; estrés; agotamiento (ôburn-outö); resistencia a la insulina asociada con la hiperactividad del eje HPA; obesidad; trastorno por atracones; anorexia; bulimia nerviosa; trastorno de la conducta; alteraciones de la conducta; alteraciones de la conducta asociadas a la demencia; alteraciones de la conducta en los adultos mayores; miedo a volar; miedo a los ascensores; miedo a los lugares pequenos; ambliopía; anorgasmia; eyaculacion retardada; disfuncion eréctil; disminucion de la libido; orgasmo anormal; pérdida de la libido; o disminucion de la sensacion orgásmica, método que comprende la administracion a un paciente que lo necesita de una cantidad terapéuticamente eficaz del Compuesto 1, que es 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales aceptables para uso farmacéutico, a un paciente que lo necesita. Reivindicacion 11: El uso de acuerdo con la reivindicacion 10, en donde el compuesto 1 es la sal del ácido bromhídrico de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. Reivindicacion 20: El compuesto de acuerdo con la reivindicacion 19, que es la sal del ácido bromhídrico de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. Reivindicacion 21: El compuesto de acuerdo con la reivindicacion 20, en donde dicha sal es cristalina. Reivindicacion 22: El compuesto de acuerdo con la reivindicacion 21, en donde dicha sal se caracteriza por tener picos mayores en los XRPD a 6,89; 9,73; 13,78 y 14,62 (°2 theta), todos +- 0,1 (°2 theta). Reivindicacion 30: 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales aceptables para uso farmacéutico para utilizar en el tratamiento de una enfermedad perteneciente al grupo: depresion, ansiedad, abuso o dolor cronico en un paciente que ha recibido medicacion con anterioridad (o aun la está recibiendo) para el tratamiento de dicha enfermedad, medicacion que se abandono o redujo (o tiene que ser abandonada o reducida) debido a consecuencias adversas relacionadas con el sueno o la actividad sexual.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701607 | 2007-11-13 | ||
| DKPA200701788 | 2007-12-14 | ||
| DKPA200801300 | 2008-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069260A1 true AR069260A1 (es) | 2010-01-06 |
Family
ID=40170671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104919A AR069260A1 (es) | 2007-11-13 | 2008-11-11 | Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9278096B2 (es) |
| EP (3) | EP3115050A1 (es) |
| JP (2) | JP5603244B2 (es) |
| KR (1) | KR101536023B1 (es) |
| CN (1) | CN102014908A (es) |
| AR (1) | AR069260A1 (es) |
| AT (1) | ATE537829T1 (es) |
| AU (1) | AU2008323390B2 (es) |
| BR (1) | BRPI0820474B8 (es) |
| CA (1) | CA2705163C (es) |
| CL (1) | CL2008003363A1 (es) |
| CO (1) | CO6270322A2 (es) |
| CY (2) | CY1112646T1 (es) |
| DK (2) | DK2431039T3 (es) |
| EA (1) | EA027783B1 (es) |
| ES (2) | ES2591110T3 (es) |
| HR (2) | HRP20120144T4 (es) |
| HU (1) | HUE029588T2 (es) |
| IL (1) | IL205466A (es) |
| LT (1) | LT2431039T (es) |
| MX (1) | MX2010004688A (es) |
| NZ (1) | NZ585247A (es) |
| PL (2) | PL2219647T3 (es) |
| PT (2) | PT2431039T (es) |
| RS (2) | RS52256B2 (es) |
| SG (1) | SG10201405001XA (es) |
| SI (2) | SI2431039T1 (es) |
| TW (1) | TW200932233A (es) |
| WO (1) | WO2009062517A1 (es) |
| ZA (1) | ZA201003350B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| KR20120065328A (ko) | 2009-08-24 | 2012-06-20 | 하. 룬드벡 아크티에셀스카브 | １-［２-（２,４-디메틸-페닐술파닐）-페닐］피페라진의 신규한 조성물 |
| TW201212918A (en) * | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| BR112013018898B1 (pt) * | 2011-01-27 | 2021-10-05 | Neuren Pharmaceuticals Limited | Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo |
| JP6078466B2 (ja) | 2011-07-21 | 2017-02-08 | 学校法人 名城大学 | セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット |
| MY171802A (en) * | 2012-12-13 | 2019-10-30 | H Lundbeck As | Compositions comprising vortioxetine and donepezil |
| JP6323979B2 (ja) * | 2013-01-17 | 2018-05-16 | 学校法人 名城大学 | うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット |
| CN105339361A (zh) * | 2013-05-31 | 2016-02-17 | 斯洛文尼亚莱柯制药股份有限公司 | 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法 |
| EP2878596A1 (en) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates |
| KR20160093025A (ko) * | 2013-12-20 | 2016-08-05 | 하. 룬트벡 아크티에 셀스카브 | 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도 |
| CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
| US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
| EP2930171A1 (en) * | 2014-04-07 | 2015-10-14 | LEK Pharmaceuticals d.d. | Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| CN108348486A (zh) * | 2015-07-17 | 2018-07-31 | 巴斯德研究院 | 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂 |
| AU2017288456A1 (en) | 2016-07-01 | 2018-12-13 | H. Lundbeck A/S | Vortioxetine dosing regimes for fast onset of antidepressant effect |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP2023520016A (ja) | 2020-04-03 | 2023-05-15 | ハー・ルンドベック・アクチエゼルスカベット | 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
| WO2023036820A1 (en) | 2021-09-10 | 2023-03-16 | H. Lundbeck A/S | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| KR20230148676A (ko) | 2022-04-18 | 2023-10-25 | 영진약품 주식회사 | 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU163075A (en) * | 1975-07-21 | 1982-05-31 | Science Union & Cie | Process for preparing new phenoxy derivatives |
| US5258387A (en) | 1990-08-21 | 1993-11-02 | Hoffmann-La Roche Inc. | Tricyclic pyridone derivatives |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| CN100457738C (zh) * | 2001-12-20 | 2009-02-04 | H·隆德贝克有限公司 | 芳氧基苯基和芳硫基苯基衍生物 |
| EP1626720B1 (en) | 2003-04-04 | 2008-09-03 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| US20060019938A1 (en) * | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
| ZA200810017B (en) * | 2006-06-16 | 2010-04-28 | Lundbeck & Co As H | 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| KR20120065328A (ko) | 2009-08-24 | 2012-06-20 | 하. 룬드벡 아크티에셀스카브 | １-［２-（２,４-디메틸-페닐술파닐）-페닐］피페라진의 신규한 조성물 |
-
2008
- 2008-11-03 TW TW097142306A patent/TW200932233A/zh unknown
- 2008-11-11 AR ARP080104919A patent/AR069260A1/es unknown
- 2008-11-12 EP EP16178423.6A patent/EP3115050A1/en not_active Withdrawn
- 2008-11-12 PT PT111932372T patent/PT2431039T/pt unknown
- 2008-11-12 HU HUE11193237A patent/HUE029588T2/en unknown
- 2008-11-12 EP EP11193237.2A patent/EP2431039B1/en active Active
- 2008-11-12 PL PL08850935T patent/PL2219647T3/pl unknown
- 2008-11-12 EA EA201070598A patent/EA027783B1/ru not_active IP Right Cessation
- 2008-11-12 DK DK11193237.2T patent/DK2431039T3/en active
- 2008-11-12 CA CA2705163A patent/CA2705163C/en active Active
- 2008-11-12 EP EP08850935.1A patent/EP2219647B2/en active Active
- 2008-11-12 SG SG10201405001XA patent/SG10201405001XA/en unknown
- 2008-11-12 CL CL2008003363A patent/CL2008003363A1/es unknown
- 2008-11-12 RS RS20120087A patent/RS52256B2/sr unknown
- 2008-11-12 ES ES11193237.2T patent/ES2591110T3/es active Active
- 2008-11-12 WO PCT/DK2008/050271 patent/WO2009062517A1/en not_active Ceased
- 2008-11-12 US US12/741,780 patent/US9278096B2/en active Active
- 2008-11-12 BR BRPI0820474A patent/BRPI0820474B8/pt active IP Right Grant
- 2008-11-12 ES ES08850935T patent/ES2379419T5/es active Active
- 2008-11-12 MX MX2010004688A patent/MX2010004688A/es active IP Right Grant
- 2008-11-12 HR HRP20120144TT patent/HRP20120144T4/hr unknown
- 2008-11-12 DK DK08850935.1T patent/DK2219647T4/da active
- 2008-11-12 PT PT08850935T patent/PT2219647E/pt unknown
- 2008-11-12 SI SI200831677A patent/SI2431039T1/sl unknown
- 2008-11-12 KR KR1020107010492A patent/KR101536023B1/ko not_active Ceased
- 2008-11-12 AU AU2008323390A patent/AU2008323390B2/en active Active
- 2008-11-12 CN CN2008801164637A patent/CN102014908A/zh active Pending
- 2008-11-12 SI SI200830548T patent/SI2219647T2/sl unknown
- 2008-11-12 PL PL11193237.2T patent/PL2431039T3/pl unknown
- 2008-11-12 AT AT08850935T patent/ATE537829T1/de active
- 2008-11-12 LT LTEP11193237.2T patent/LT2431039T/lt unknown
- 2008-11-12 RS RS20160756A patent/RS55147B1/sr unknown
- 2008-11-12 JP JP2010533436A patent/JP5603244B2/ja active Active
- 2008-11-12 NZ NZ585247A patent/NZ585247A/en not_active IP Right Cessation
-
2010
- 2010-04-29 IL IL205466A patent/IL205466A/en active IP Right Grant
- 2010-05-12 ZA ZA2010/03350A patent/ZA201003350B/en unknown
- 2010-05-13 CO CO10057476A patent/CO6270322A2/es not_active Application Discontinuation
-
2012
- 2012-02-24 CY CY20121100199T patent/CY1112646T1/el unknown
-
2014
- 2014-05-14 JP JP2014100815A patent/JP5841636B2/ja active Active
-
2016
- 2016-02-12 US US15/043,167 patent/US9744166B2/en active Active
- 2016-09-01 HR HRP20161121TT patent/HRP20161121T1/hr unknown
- 2016-09-07 CY CY20161100885T patent/CY1117978T1/el unknown
-
2017
- 2017-07-27 US US15/661,392 patent/US20180161321A1/en not_active Abandoned
-
2020
- 2020-05-12 US US15/930,014 patent/US11628166B2/en active Active
-
2023
- 2023-04-04 US US18/130,749 patent/US20240082239A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069260A1 (es) | Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. | |
| JP5901528B2 (ja) | 線維筋痛症候群の治療方法 | |
| JP5024635B2 (ja) | 睡眠覚醒障害の治療 | |
| RU2006140964A (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
| RU2008150622A (ru) | Лечение агонистом мелатонина | |
| CN1711101A (zh) | 孤独症及相似障碍的治疗 | |
| US10647679B2 (en) | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto | |
| JP2007506801A (ja) | モダフィニルおよび他の薬剤を含んでなる製薬学的組成物 | |
| AR069904A1 (es) | Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptables | |
| US10682343B2 (en) | Snoring treatment | |
| Kobayashi et al. | Ketamine for acute catatonia: A case report | |
| ES2206400T3 (es) | Utilizacion de modafinilo para la preparacion de un medicamento destinado a corregir los trastornos de la vigilia asociados a las miopatias. | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| KR20080047299A (ko) | 스미스-마제니스 증후군 치료용 약제 제조시 아고멜라틴의용도 | |
| MX2012003212A (es) | Papel del acido n-2-hidroxi-etil-piperazina-n´-2-etano sulfonico (hepes) en el control del dolor y reversion de lesiones por desmielinizacion. | |
| US20110065749A1 (en) | Method and pharmaceutical composition for treatment of mental disorders | |
| CN1980652A (zh) | 睡眠障碍的预防和/或治疗剂 | |
| JP7773909B2 (ja) | 筋痛性脳脊髄炎／慢性疲労症候群治療剤 | |
| CN113015524A (zh) | 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途 | |
| TH1801007211A (th) | องค์ประกอบสำหรับการบำบัดกลุ่มอาการด้านลบในผู้ป่วยที่ไม่ได้เป็นโรคจิตเภท | |
| CN1712403A (zh) | 用于预防或治疗阳痿新型2－苯基取代的咪唑并三嗪酮化合物 | |
| RU2007136809A (ru) | Способ лечения функциональных психических расстройств при шизофрении и аффективном психозе | |
| Arpaci et al. | Anesthetic approach to patient with Down syndrome and Hallervorden-Spatz disease who underwent tooth extraction | |
| WO2025163129A1 (en) | Acetyl-leucine for treating parkinson´s disease | |
| TW202519202A (zh) | 3-[(苯並[d][1,3]二氧戊環-4-基)-氧基]-3-芳基丙胺類化合物在製備治療性功能障礙的藥物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |